Australia's pharmaceutical patent landscape has reached a critical juncture, with appellate courts reconsidering fundamental principles of patent scope, term extensions, and remedies that will shape originator-generic disputes for the foreseeable future. As the High Court prepares to rule on patent term extensions for formulation patents and new Federal Court practice directions take effect, the strategic calculus for both innovators and generic entrants is being fundamentally rewritten.
AustraliaIntellectual Property
The past twelve months have marked a notable inflection point for pharmaceutical patent law in Australia, with appellate courts revisiting foundational questions of patent scope and remedies that will set the direction of originator-generic disputes for years to come.
Several major pharmaceutical patent disputes still before the Court (Pfizer v Samsung (etanercept) and Otsuka v Generic Health (aripiprazole – Government damages)) have moved closer to final resolution, while a number of new cases have also been filed. As the Federal Court’s new practice directions designed to streamline patent litigation now taking effect, we expect to see meaningful procedural efficiencies in how these cases are managed. We hope that bringing these developments together serves as a practical resource for navigating this evolving terrain.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
The content of this article is intended to provide a general guide
to the subject matter. Specialist advice should be sought about your
specific circumstances.
View source
